A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L4-L5

被引:48
作者
Brower, Richard S. [1 ]
Vickroy, Nancy M. [1 ]
机构
[1] N Coast Spine Ctr, Akron, OH 44310 USA
关键词
bone morphogenetic protein (BMP-2); fusion; heterotopic ossification; off-label; psoas;
D O I
10.1097/BRS.0b013e31817c4f1c
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Study Design. Case report. Objective. Describe a complication from the use of bone morphogenetic protein-2 (BMP-2) for posterolateral lumbar fusion. Summary of Background Data. N/A, case report. Methods. The patient is a 69-year-old white male with a 1 year history of back and right leg pain with a foot drop due to spinal stenosis and a degenerative spondylolisthesis at L4-L5. Surgery for decompression and instrumented fusion was performed using BMP. Results. Within 3 months after surgery the patient developed pain along his iliac wing, groin, and greater trochanter on the right side. Work up over the next several months included a bone scan, radiographs, Dexa scan, computed tomography scan, and magnetic resonance imaging with gadolinium and fat suppression. These tests showed extensive bone formation in the psoas and iliacus on the right side. The bone has persisted at least 2 years after surgery and shows no sign of resorption. Conclusion. BMP-2 can cause heterotopic bone formation when used for posterolateral lumbar fusion.
引用
收藏
页码:E653 / E655
页数:3
相关论文
共 11 条
[1]   Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate [J].
Boden, SD ;
Martin, GJ ;
Morone, MA ;
Ugbo, JL ;
Moskovitz, PA .
SPINE, 1999, 24 (12) :1179-1185
[2]   Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device [J].
Burkus, JK ;
Heim, TE ;
Gornet, MF ;
Zdeblick, TA .
JOURNAL OF SPINAL DISORDERS & TECHNIQUES, 2003, 16 (02) :113-122
[3]   Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2 [J].
Burkus, JK ;
Dorchak, JD ;
Sanders, DL .
SPINE, 2003, 28 (04) :372-377
[4]   Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages [J].
Burkus, JK ;
Gornet, MF ;
Dickman, CA ;
Zdeblick, TA .
JOURNAL OF SPINAL DISORDERS & TECHNIQUES, 2002, 15 (05) :337-349
[5]  
DAVID SM, 1995, T INT SOC STUDY LUMB, V22, P14
[6]   Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft [J].
Dimar, John R. ;
Glassman, Steven D. ;
Burkus, Kenneth J. ;
Carreon, Leah Y. .
SPINE, 2006, 31 (22) :2534-2539
[7]   Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: Important lessons learned regarding dose, carrier, and safety [J].
Martin, GJ ;
Boden, SD ;
Morone, MA ;
Moskovitz, YA .
JOURNAL OF SPINAL DISORDERS, 1999, 12 (03) :179-186
[8]  
NARAGHI F, 2006, SPINE J, V6, pS7
[9]   Controlling bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth using fibrin glue [J].
Patel, VV ;
Zhao, L ;
Wong, P ;
Kanim, L ;
Bae, HW ;
Pradhan, BB ;
Delamarter, RB .
SPINE, 2006, 31 (11) :1201-1206
[10]   Safety profile for the clinical use of bone morphogenetic proteins in the spine [J].
Poynton, AR ;
Lane, JM .
SPINE, 2002, 27 (16) :S40-S48